Engineered immune cells take on stubborn blood disorder
NCT ID NCT07416032
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial will test a new type of CAR T-cell therapy, called QT-019C, in 27 adults with refractory immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding. The therapy uses donor-derived immune cells engineered to target two proteins (CD19 and BCMA) on the cells driving the disease. The main goals are to check safety and see if it can raise platelet counts.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Universal allogeneic CAR T-cells targeting CD19 and BCMA (QT-019C)
What this could lead to
If successful, this could point toward a new treatment option for patients with hard-to-treat immune thrombocytopenia, potentially reducing bleeding risk.
What could go wrong
This is a very early, small trial (27 people) focused on safety. The therapy may not work, and side effects like cytokine release syndrome or neurological issues are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNE THROMBOCYTOPENIA (ITP) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, 430022, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••